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Abstract
Background The costs of combination antiretroviral ther-
apy (cART) for HIV, consisting of separate, particularly
generic, components (multiple-tablet regimens, MTR) are
generally much lower than those of single-tablet regimens
(STR) comprising the same active ingredients.
Objectives To assess whether patients would be willing to
take MTR, once-daily, instead of STR, with the goal of
reducing general healthcare costs. In addition, we aimed to
examine whether willingness was associated with particu-
lar patient characteristics.
Methods Data from the ATHENA cohort database in The
Netherlands of adult HIV-1-infected patients in care and
taking cART C6 months were used to select 1000 potential
participants for an online patient survey on patient prefer-
ences and satisfaction. Participants were asked whether
they would be willing to take three pills with the equivalent
active ingredients simultaneously instead of STR to reduce
costs. Multivariate logistic regression was used to examine
associations between patient characteristics and willingness
to take MTR instead of STR.
Results Forty-seven percent (n = 152) of the 322 respon-
dents answered ‘yes’ and 26 % (n = 83) answered
‘maybe’ when asked whether they would be willing to take
three pills with the equivalent active ingredients simulta-
neously to reduce costs. Non-Dutch patients were signifi-
cantly more likely to answer ‘no’ (OR: 2.49; 95 % CI:
1.17–5.30) or ‘maybe’ (OR: 2.63; 95 % CI: 1.24–5.60).
Answering ‘no’ was less common among patients who had
been taking cART C15 years (OR: 0.23; 95 % CI:
0.09–0.58). Commonly reported concerns included the
dosing frequency, efficacy and tolerability of MTR.
Conclusions HIV-infected patients do not necessarily
oppose the decision to prescribe MTR instead of STR to
reduce healthcare costs. However, the potential trade-off in
terms of convenience should be carefully weighed against
the projected savings.
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Key Points
With the growing availability of generic
antiretroviral agents for HIV, switching from single-
tablet regimens to multiple-tablet regimens is widely
considered to be a strategy to reduce healthcare
costs. Patients’ attitudes towards this issue have not
been assessed.
Our study shows that HIV-infected patients in The
Netherlands do not necessarily oppose the decision
to switch to multiple-tablet regimens for economic
reasons. Region of origin and duration of
combination antiretroviral therapy (cART) usage
may play a role in patients’ opinions on this matter.
Common concerns included dosing frequency,
efficacy and tolerability of multiple-tablet regimens,
and should be carefully addressed in both decision
making and in informing the patient.
1 Introduction
The development of combination antiretroviral therapy
(cART) has led to remarkable improvements in life
expectancy and quality of life for those infected with
human immunodeficiency virus (HIV) [1]. Not only are
cART regimens increasingly potent, they have also been
greatly simplified. Regimens have evolved from combi-
nations involving more than 20 pills taken several times per
day to co-formulated drugs, taken once or twice daily [2].
Currently, the use of single-tablet regimens (STR), in
which all components of a cART regimen are combined
into a single tablet administered once daily, is widely
recommended as first-line therapy [3].
In contrast to these developments, there has been a
recent shift towards the use of non-co-formulated cART
generics in the form of multiple-tablet regimens (MTR).
These MTR are less expensive than branded STR combi-
nations. In a pharmacoeconomic analysis, Walensky et al.
[4] demonstrated that a switch from STR (efavirenz-
emtricitabine–tenofovir) to MTR (generic efavirenz, gen-
eric lamivudine and tenofovir) in the USA would save
nearly US$1 billion in the first year. Another study in the
UK showed that switching all patients to available generics
could save an estimated £1.1 billion in 5 years [5].
While the range of available generics, and therefore the
options for saving costs through MTR, is expanding, it is
unclear to what extent switching to MTR would affect
adherence and virological outcomes [6]. Despite the con-
siderable amount of evidence supporting the positive
impact of a lower pill burden (number of pills) and dosing
frequency on adherence [7–9], few clinical data support the
superior effectiveness of STR versus its separate compo-
nents [3]. Indeed, there is evidence suggesting that STR
and once-daily MTR are equally effective [10]. In recent
studies evaluating the impact of cost-saving policies,
switching to MTR did not affect clinical outcomes [3, 11,
12]. Additional studies supporting equivalence of STR and
MTR include a meta-analysis of 19 RCTs [13] and a
prospective cohort study [14] in which a lower pill burden
in once-daily regimens did not predict better adherence.
The above-mentioned studies have provided evidence of
cost savings and equivalent efficacy, but have not evaluated
patients’ attitudes towards taking MTR. Therefore, we
assessed whether patients in The Netherlands would be
willing to take MTR, once daily, instead of STR with the
goal of reducing costs. In addition, we aimed to identify
patient characteristics potentially associated with willing-
ness to take MTR.
2 Methods
2.1 Study Population
In The Netherlands, all HIV-infected patients are treated in
designated HIV treatment centres, and prospectively
monitored in the ‘AIDS therapy evaluation in The
Netherlands’ (ATHENA) cohort (maintained by Stichting
HIV Monitoring, SHM) [15]. We selected 1,000 HIV-1-
infected patients from all treatment centres for participation
in a larger study (Q-HIV) in which we assessed patients’
health-related quality of life and perspectives on outpatient
HIV care. The treatment centre size was taken into account,
ensuring a minimum of 20 potential participants per
treatment centre. We selected chronically infected patients
with: (1) time since initiation of cART C6 months; and (2)
age C18 years at the time of diagnosis. For the selection,
we used the anonymized study ID number assigned to each
HIV patient in care by SHM.
Selected potential participants were provided with an
information letter and a password for accessing an online
questionnaire in Dutch or English. We also offered a paper
version of the questionnaire. The study was exempted from
written informed consent (by the Medical Ethics Review
Committee of the Academic Medical Centre of the
University of Amsterdam); we considered consent implicit
when a questionnaire was returned to us.
2.2 Outcome Measures
The participants were asked as follows whether they would
be willing to take an MTR (once daily) instead of an STR
to reduce costs:
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‘‘The costs of medication are being critically assessed
worldwide. The costs of 3 separate pills are generally much
lower than the cost of a combination drug with the same
active ingredients. Would you be willing to take 3 pills at
the same time instead of 1 pill?
Respondents could answer ‘yes’, ‘no’ or ‘maybe’. In
addition, patients were given the opportunity to comment
on the matter (‘‘Please fill in your comment here:…’’). We
assessed the comments per group (‘yes’, ‘no’ or ‘maybe’).
2.3 Patient Characteristics
We used the ATHENA cohort database to extract the
patient characteristics of age, sex, region of origin,
socioeconomic status (SES), route of HIV transmission,
time since cART initiation and time since diagnosis.
Region of origin was based on the country of birth and
grouped into The Netherlands, Sub-Saharan Africa (SSA)
and ‘other’. For the SES we used a classification system
previously described by The Netherlands Institute for
Social Research [16]. Here, the five classes, based on area
codes, were recoded as high, middle or low. Route of
transmission was categorized as men who have sex with
men (MSM), heterosexual contact or ‘other/unknown’.
2.4 Statistical Analysis
We used t tests, Mann–Whitney U tests and v2 analysis to
test for differences in characteristics between respondents
and non-respondents. Then, we stratified the proportions of
respondents answering ‘yes’, ‘no’ or ‘maybe’ according to
characteristics, and used v2 analysis to determine statisti-
cally significant differences in proportions between groups.
Using multinomial logistic regression, we assessed
potential associations between patient characteristics and
answering the question with ‘yes’, ‘no’ or ‘maybe’. In this
analysis, which accommodates three outcomes, we esti-
mated the odds of answering ‘no’ versus ‘yes’ and the odds
of answering ‘maybe’ versus ‘yes’. We recoded region of
origin as either from The Netherlands (Dutch) or ‘other’
(non-Dutch), and combined sex and transmission route
(MSM, heterosexual male, heterosexual female and
‘other’). Variables with p values \0.1 in the univariate
analysis were entered in a multivariate model. All analyses
were performed with STATA (version 13).
3 Results
Of the 1000 selected patients, 958 patients were eligible for
participation (i.e. had not recently died, migrated or swit-
ched to another treatment centre). A total of 331 patients
from all HIV-treatment centres in The Netherlands
completed the questionnaire (response rate: 35 %) and 322
answered the question regarding switching to MTR.
Twenty-five percent of respondents chose to complete the
paper version of the questionnaire.
The proportions of males (85 %), patients originating
from The Netherlands (77 %) and MSM (71 %) were
significantly higher among respondents than among non-
respondents (73, 50 and 48 %, respectively). Respondents
were significantly older than non-respondents (average of
51 vs. 47 years) and had a higher SES. The groups did not
differ with regard to duration of HIV-infection or time
since cART initiation. Of the 322 respondents, 47 %
(n = 152) answered ‘yes’, 27 % (n = 87) answered ‘no’
and 26 % (n = 83) answered ‘maybe’ when asked whether
they would be willing to use an MTR to reduce costs.
Table 1 shows the proportions of respondents answering
this question with ‘yes’, ‘no’ or ‘maybe’ according to
patient characteristics. An affirmative answer was rela-
tively more common among older patients, men, Dutch
patients, MSM and patients with a time since diagnosis or
cART initiation of C15 years. Female respondents and
respondents from SSA were most likely to answer the
question with ‘maybe’. Finally, patients taking MTR were
more likely to answer the question with ‘yes’.
3.1 Respondents Answering ‘Yes’, ‘No’ or ‘Maybe’
Table 2 shows the odds of respondents answering ‘no’
versus ‘yes’ and ‘maybe’ versus ‘yes’. In the multivariate
analyses, non-Dutch patients were significantly more likely
to answer ‘no’ (OR: 2.49; 95 % CI: 1.17–5.30) or ‘maybe’
(OR: 2.63; 95 % CI: 1.24–5.60). Answering the question
with ‘no’ was less common among patients who had been
taking cART C15 years (OR: 0.23; 95 % CI: 0.09–0.58).
3.2 Views and Concerns
A total of 105 patients expressed their views in the com-
ment field. Respondents reported that they would consider
switching to MTR a step backwards (n = 24) and
emphasized the importance of taking the pills once daily
(n = 6). Four patients felt that the high STR prices were
driven by the pharmaceutical industry and indicated that
pricing is a political matter.
Respondents who answered ‘maybe’ pointed out that
potency and tolerability of the regimen should not be
inferior to STR (n = 5). Having to pay for medication was
reported as a reason to consider switching to an MTR
(n = 3). The most common view of respondents who
answered ‘no’ was that STR are more convenient, partic-
ularly when travelling or at work (n = 8). Other reasons
for reluctance included difficulties swallowing pills
(n = 4), increased risk of dosage errors (n = 3), concerns
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about perceiving oneself as more ill (n = 3) and concerns
about side effects (n = 2).
4 Discussion
With the growing availability of generic antiretroviral
agents, switching from STR to MTR is widely being
considered as a strategy to reduce healthcare costs. In
some settings, this switch has been structurally
implemented [3, 11, 12]. The decision to take this mea-
sure, which is intuitively paradoxical to the simplification
of cART regimens, must be preceded by an assessment of
the efficacy of STR versus MTR, estimated savings and
patient preferences.
Our study suggests that a considerable proportion of
HIV-infected patients in The Netherlands would consider
switching to MTR for economic reasons. Almost half the
respondents answered ‘yes’ and a quarter answered
‘maybe’ when asked whether they would be willing to take
Table 1 Characteristics of
respondents answering ‘yes’,
‘no’ or ‘maybe’ to the question
whether they would be willing
to switch from a single-drug
regimen to multiple pills (once
daily) for the treatment of HIV
Characteristic Yes No Maybe p value
n = 152 (47 %) n = 87 (27 %) n = 83 (26 %)
Age (years)
\40 19 (37 %) 21 (41 %) 11 (22 %) 0.046
40–50 43 (43 %) 32 (31 %) 27 (26 %)
50–60 53 (53 %) 17 (17 %) 30 (30 %)
[60 37 (54 %) 17 (24 %) 15 (22 %)
Sex
Male 139 (50 %) 73 (27 %) 64 (23 %) 0.009
Female 13 (28 %) 14 (31 %) 19 (41 %)
Region of origin
The Netherlands 133 (53 %) 61 (24 %) 58 (23 %) <0.001
Sub-Saharan Africa 1 (4 %) 9 (38 %) 14 (58 %)
Other 18 (39 %) 17 (37 %) 11 (24 %)
Socioeconomic status
High 47 (52 %) 22 (24 %) 22 (24 %) 0.087
Middle 56 (51 %) 23 (20 %) 32 (29 %)
Low 46 (41 %) 41 (37 %) 25 (22 %)
Missinga 3 (38 %) 1 (12 %) 4 (50 %)
Route of HIV transmission
MSM 123 (53 %) 58 (25 %) 52 (22 %) 0.027
Heterosexual 24 (33 %) 24 (33 %) 25 (34 %)
Other/unknown 5 (30 %) 5 (35 %) 6 (35 %)
Time since cART initiation (years)
\5 32c (40 %) 29 (36 %) 19 (24 %) 0.002
5–10 46 (47 %) 28 (29 %) 23 (24 %)
10–15 25 (35 %) 20 (28 %) 26 (37 %)
[15 49 (67 %) 10 (13 %) 15 (20 %)
Time since diagnosis (years)
\5 17 (45 %) 10 (26 %) 11 (29 %) 0.012
5–10 46 (43 %) 38 (36 %) 23 (21 %)
10–15 34 (39 %) 26 (29 %) 28 (32 %)
[15 55 (62 %) 13 (15 %) 21 (23 %)
Currently on STR
No 134 (59 %) 35 (15 %) 59 (26 %) <0.001
Yes 18 (19 %) 52 (55 %) 24 (26 %)
p values for the comparison of characteristics (v2 analysis)
Bold denotes significant p value (\0.05)
cART combination antiretroviral therapy, MSM men who have sex with men, STR single-tablet regimen
a ‘Missing’ group not included in analysis
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three pills with the equivalent active ingredients simulta-
neously instead of one pill.
Our results show that patients’ willingness to switch to
MTR is to some extent dependent on how long they have
been taking cART. Patients who had been taking cART
C15 years were more willing to take MTR, possibly
because they experienced the years in which cART reg-
imens were far more complex. Conversely, non-Dutch
respondents were less willing to take MTR. A possible
explanation for this could be that non-Dutch patients are
more likely to have disclosure concerns, as reported in a
previous study among HIV-infected patients in The
Netherlands [17]. Patients preferring not to disclose their
HIV-serostatus report more medication hiding [18, 19],
and hiding medication may be perceived as easier with
STR.
Our quantitative results show that patients (including
respondents willing to switch) feel that switching to MTR
is a step backwards. In addition, the most common con-
cerns appear to be the dosing frequency, efficacy and tol-
erability of MTR. Thus, these matters deserve attention in
both decision making and in informing the patient
regarding MTR.
4.1 Strengths and Limitations
We consider the fact that we have data from all the treat-
ment centres in the country to be a strength of this study.
Table 2 Univariate and multivariate multinomial logistic regression analysis for respondents answering ‘no’ or ‘maybe’ versus ‘yes’ to the
question of whether they would be willing to switch from a single-drug regimen to multiple pills (once daily) for the treatment of HIV
Characteristic ‘No’ vs. ‘yes’ ‘Maybe’ vs. ‘yes’
Univariate
OR (95 % CI)
Multivariate
OR (95 % CI)
Univariate
OR (95 % CI)
Multivariate
OR (95 % CI)
Age (years)
\40 1 1 1 1
40–50 0.67 (0.31–1.46) 1.05 (0.45–2.45) 1.08 (0.45–2.63) 1.56 (0.59–4.11)
50–60 0.29** (0.13–0.66) 0.61 (0.24–1.56) 0.98 (0.41–2.33) 1.83 (0.67–5.01)
C60 0.42* (0.18–0.97) 0.90 (0.34–2.36) 0.70 (0.27–1.82) 1.26 (0.42–3.74)
Sex and route of transmission
MSM 1 1 1 1
Heterosexual, male 1.77 (0.72–4.33) 1.60 (0.60–4.25) 1.97 (0.80–4.85) 1.66 (0.62–4.47)
Heterosexual, female 2.47* (1.08–5.68) 1.90 (0.74–4.91) 2.96* (1.30–6.75) 2.54 (1.00–6.47)
Other 2.12 (0.59–7.61) 1.52 (0.37–6.24) 2.84 (0.83–9.71) 2.16 (0.54–8.61)
Region of origin
The Netherlands 1 1 1 1
Other 2.98** (1.53–5.80) 2.49* (1.17–5.30) 3.02** (1.54–5.91) 2.63* (1.24–5.60)
Socioeconomic status
High 1 1 1 1
Middle 0.88 (0.44–1.77) 0.79 (0.37–1.70) 1.22 (0.63–2.38) 0.98 (0.47–2.03)
Low 1.90 (0.99–3.68) 1.72 (0.84–3.54) 1.16 (0.58–2.34) 1.02 (0.48–2.17)
Time since cART initiation (years)
\5 1 1 1 1
5–10 0.67 (0.34–1.34) 0.59 (0.28–1.22) 0.84 (0.40–1.79) 0.81 (0.37–1.79)
10–15 0.88 (0.41–1.91) 0.98 (0.42–2.30) 1.75 (0.80–3.86) 1.59 (0.67–3.81)
C15 0.23** (0.10–0.52) 0.23** (0.09–0.58) 0.52 (0.23–1.16) 0.42 (0.17–1.02)
Time since HIV diagnosis (years)a
\5 1 – 1 –
5–10 1.40 (0.58–3.42) – 0.77 (0.31–1.92) –
10–15 1.30 (0.51–3.31) – 1.27 (0.51–3.16) –
C15 0.40 (0.15–1.08) – 0.59 (0.24–1.47) –
cART combination antiretroviral therapy, MSM men who have sex with men
* p\ 0.05, **p\ 0.01, ***p\ 0.001
a Time since diagnosis was not included in the multivariate model because of collinearity (time since cART initiation)
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Furthermore, we offered the option of completing out a
paper version of the questionnaire, to reduce sampling bias
that can occur when collecting patient-reported data online
[20]. Finally, the open-ended nature in which respondents
could state their views and concerns provided us with a
variety of information that we could not have anticipated
had we chosen to offer a limited number of answers.
Despite efforts to recruit a nationally representative
sample of individuals with HIV, patients from The
Netherlands, MSM and patients with a higher SES were
over-represented in our study sample, possibly resulting in
a higher overall percentage of willingness to switch.
Another limitation is the hypothetical character of our
question (limited to ‘once daily’ dosage), with responses
possibly not predictive for willingness in a real-life setting.
In addition, given our aim to assess views in a cross-section
of the HIV population, we posed the question to patients
who were not on single-drug regimens at the time of par-
ticipation. The response of those on STR (19 % willing to
switch) and those on MTR (59 % willing to switch) may
need to be interpreted differently. On the one hand, the
individuals of concern in this matter (i.e. those on STR)
have a strong preference for STR. On the other hand, one
could argue that experience with multiple pills is not dis-
couraging to the extent that, when given the (hypothetical)
choice, patients would be reluctant to switch to MTR.
With regards to the generalizability of our results, it is
important to bear in mind that in The Netherlands, where
all citizens are legally required to be insured, there is
universal access to cART (without co-payment). In settings
where this is not the case, individual financial factors are
likely to play to an important role in patients’ positions
regarding this matter.
4.2 Implications
This exploratory study shows that patients’ preferences are
not necessarily a reason to disregard the option of pre-
scribing MTR. Our results suggest that, if well informed
about the efficacy and tolerability, patients may find
switching to MTR for economic reasons acceptable.
In particular, our results suggest that patients from The
Netherlands and patients who have been taking cART for
C15 years (a substantial proportion of the HIV-infected
population in The Netherlands) may be more likely to
approve a switch to MTR. For patients more reluctant to
switch, further inquiry into the concerns they may have is
important. Our results suggest that these may include
potency, tolerability, inconvenience and swallowing diffi-
culties. Other issues to cover in clinical practice will differ
per setting and include the financial consequences for the
individual patient, the option to switch back to STR and
dosing frequency.
5 Conclusion
HIV-infected patients do not necessarily oppose the deci-
sion to prescribe MTR instead of STR to reduce healthcare
costs. However, the potential trade-off in terms of conve-
nience should be carefully weighed against the projected
savings. Moreover, considering the scarcity of evidence on
the efficacy and safety of switching to MTR [3, 13], out-
comes of such switches should be closely monitored over
the long term.
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Pronk, F.A. van Truijen-Oud. HIV clinical virologists/chemists: W.
A. van der Reijden, R. Jansen. OLVG, Amsterdam: HIV treating
physicians: K. Brinkman*, G.E.L. van den Berk, W.L. Blok, P.H.J.
Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. HIV nurse
consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene,
I.B. van der Meche´, M. Spelbrink, H. Sulman, A.J.M. Toonen, S.
Wijnands. HIV clinical virologists: M. Damen, D. Kwa. Data col-
lection: E. Witte. Radboudumc, Nijmegen: HIV treating physicians:
R. van Crevel*, P.P. Koopmans, M. Keuter, A.J.A.M. van der Ven,
H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse consultants: M.
Albers, M.E.W. Bosch, K.J.T. Grintjes-Huisman, B.J. Zomer. HIV
clinical virologists/chemists: F.F. Stelma, J. Rahamat-Langendoen.
HIV clinical pharmacology consultant: D. Burger. Rijnstate, Arn-
hem: HIV treating physicians: C. Richter*, E.H. Gisolf, R.J. Hassing.
HIV nurse consultants: G. ter Beest, P.H.M. van Bentum, N.
Langebeek. HIV clinical virologists/chemists: R. Tiemessen, C.M.A.
Swanink. Spaarne Gasthuis, Haarlem: HIV treating physicians:
S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants: N.
Hulshoff, L.M.M. van der Prijt, J. van der Swaluw. Data collection:
N. Bermon. HIV clinical virologists/chemists: W.A. van der Reijden,
R. Jansen, B.L. Herpers, D.Veenendaal. Medisch Centrum Jan van
Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen.
HIV nurse consultants: M. van Wijk. St Elisabeth Ziekenhuis, Til-
burg: HIV treating physicians: M.E.E. van Kasteren*, A.E. Brouwer.
HIV nurse consultants and data collection: B.A.F.M. de Kruijf-van de
Wiel, M. Kuipers, R.M.W.J. Santegoets, B. van der Ven. HIV clinical
virologists/chemists: J.H. Marcelis, A.G.M. Buiting, P.J. Kabel.
Universitair Medisch Centrum Groningen, Groningen: HIV
treating physicians: W.F.W. Bierman*, H. Scholvinck, K.R. Wilting,
Y. Stienstra. HIV nurse consultants: H. de Groot-de Jonge, P.A. van
der Meulen, D.A. de Weerd, J. Ludwig-Roukema. HIV clinical
virologists/chemists: H.G.M. Niesters, A. Riezebos-Brilman, C.C.
van Leer-Buter, M. Knoester. Universitair Medisch Centrum
Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, T.
Mudrikova, P.M. Ellerbroek, J.J. Oosterheert, J.E. Arends, R.E. Barth,
M.W.M. Wassenberg, E.M. Schadd. HIV nurse consultants: D.H.M.
van Elst-Laurijssen, E.E.B. van Oers-Hazelzet, S. Vervoort, Data
collection: M. van Berkel. HIV clinical virologists/chemists: R.
Schuurman, F. Verduyn-Lunel, A.M.J. Wensing. VUmc, Amster-
dam: HIV treating physicians: E.J.G. Peters*, M.A. van Agtmael, M.
Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M.
Laan. HIV clinical virologists/chemists: A.M. Pettersson, C.M.J.E.
Vandenbroucke-Grauls, C.W. Ang. Wilhelmina Kinderziekenhuis,
UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, T.F.W.
Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta.
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